Bicara Therapeutics Inc.
NGM: BCAXLive Quote
About Bicara Therapeutics Inc.
Healthcare
Biotechnology
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
📊 Fundamental Analysis
Bicara Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -30.9%, which indicates that capital utilization is currently under pressure.
At a current price of $21.12, BCAX currently trades near the top of its 52-week range (94%) (Range: $7.80 - $22.01).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.35B
Trailing P/E
--
Forward P/E
-6.95
Beta (5Y)
--
52W High
$22.01
52W Low
$7.80
Avg Volume
540K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App